Page last updated: 2024-10-26

2-amino-7-phosphonoheptanoic acid and Parkinson Disease

2-amino-7-phosphonoheptanoic acid has been researched along with Parkinson Disease in 1 studies

2-amino-7-phosphonoheptanoic acid: (D)-isomer active as an antagonist of N-methyl-D-aspartate excitation of central neurons; (L)-isomer inactive; RN given refers to cpd without isomeric designation

Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Turski, L1
Klockgether, T1
Turski, WA1
Schwarz, M1
Sontag, KH1

Other Studies

1 other study available for 2-amino-7-phosphonoheptanoic acid and Parkinson Disease

ArticleYear
Blockade of excitatory neurotransmission in the globus pallidus induces rigidity and akinesia in the rat: implications for excitatory neurotransmission in pathogenesis of Parkinson's diseases.
    Brain research, 1990, Mar-26, Volume: 512, Issue:1

    Topics: 2-Amino-5-phosphonovalerate; Amino Acids; Animals; Corpus Striatum; Dose-Response Relationship, Drug

1990